Nebilox (Nebivolol)

Nebivolol belongs to the beta‑blocker class and is used to manage cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure in adults.
• Chronic heart failure (reduced ejection fraction): improves cardiac output and reduces symptoms.
• Elderly patients with hypertension: provides effective blood‑pressure control with a favorable side‑effect profile.

• Nebivolol exerts its antihypertensive effect primarily by selectively antagonizing β1‑adrenergic receptors in cardiac tissue, which decreases heart rate and myocardial contractility, thereby reducing cardiac output. In addition, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide release and vasodilation of peripheral vessels, further contributing to blood pressure reduction. The combined β1‑blockade and nitric‑oxide mediated vasodilation produce a synergistic lowering of systemic vascular resistance without significant β2‑receptor inhibition, preserving bronchial tone and metabolic function.

Nebivolol may be associated with a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects

• Headache: mild to moderate headache.
• Dizziness: especially on standing.
• Fatigue: feeling of tiredness.
• Nasal congestion: stuffy nose.

Serious or Rare Side Effects

• Bradycardia: abnormally slow heart rate.
• Heart block: AV conduction disturbances.
• Severe bronchospasm: difficulty breathing in susceptible individuals.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use.

• Cardiovascular assessment: evaluate heart rate and rhythm before initiation.
• Concomitant β‑blockers: avoid combining with other β‑blockers to prevent excessive β‑blockade.
• Asthma or COPD: use with caution due to potential bronchoconstriction.
• Diabetes: monitor blood glucose as β‑blockade may mask hypoglycemia symptoms.
• Liver impairment: dose adjustment may be required in moderate to severe hepatic dysfunction.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors: may increase nebivolol plasma levels, risking bradycardia.
• Other β‑blockers: additive negative chronotropic effects can cause severe bradycardia or heart block.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (verapamil, diltiazem): may enhance bradycardic effect.
• Antihypertensive agents (ACE inhibitors, diuretics): may cause excessive blood pressure reduction.
• Antidiabetic drugs: β‑blockade may mask hypoglycemia symptoms, requiring glucose monitoring.